Radium Ra-223 Dichloride Patent Expiration
Radium Ra-223 Dichloride is Used for managing bone metastases. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Radium Ra-223 Dichloride Patents
Given below is the list of patents protecting Radium Ra-223 Dichloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xofigo | US8791127 | Mucosal bioadhesive slow release carrier for delivering active principles | Mar 23, 2027 | Bayer Hlthcare |
| Xofigo | US6635234 | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning |
Jan 03, 2020
(Expired) | Bayer Hlthcare |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Radium Ra-223 Dichloride's patents.
Latest Legal Activities on Radium Ra-223 Dichloride's Patents
Given below is the list recent legal activities going on the following patents of Radium Ra-223 Dichloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Dec, 2021 | US8791127 |
| Email Notification Critical
| 22 Sep, 2020 | US8791127 |
| Mail O.P. Petition Decision | 22 Sep, 2020 | US8791127 |
| Mail-Petition Decision - Granted | 17 Sep, 2020 | US8791127 |
| Petition Decision - Granted Critical
| 16 Sep, 2020 | US8791127 |
| O.P. Petition Decision | 14 Sep, 2020 | US8791127 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 16 Jun, 2020 | US8791127 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 15 Jun, 2020 | US8791127 |
| Email Notification Critical
| 15 Jun, 2020 | US8791127 |
| Correspondence Address Change Critical
| 10 Jun, 2020 | US8791127 |
Radium Ra-223 Dichloride's Family Patents
